Predictive Performance of Serum S100B
COX
LDH
ROC
S100B
melanoma
meta-analysis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
09
2021
accepted:
11
11
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Currently, no consensus on the use of blood tests for monitoring disease recurrence in patients with resected melanoma exists. The only meta-analysis conducted in 2008 found that elevated serum S100B levels were associated with significantly worse survival in melanoma patients. Serum LDH is an established prognostic factor in patients with advanced melanoma. To compare the discriminative and prognostic ability of serum S100B with that of serum LDH in patients with melanoma. This systematic review and meta-analysis were reported in accordance with the PRISMA Statement. The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO; CRD42019137138). A quantitative analysis of data from 6 eligible studies included 1,033 patients with cutaneous melanoma. The discriminative ability of serum S100B at identifying disease relapse [pooled Area Under the ROC (AUROC) 78.64 (95% CI 70.28; 87.01)] was significantly greater than the discriminative ability of serum LDH [AUROC 64.41 (95% CI 56.05; 7278)] (p=0.013). Ten eligible studies with 1,987 patients were included in the risk of death analysis. The prognostic performance of serum S100B [pooled estimate of adjusted hazard ratio (HR) 1.78 (95% CI 1.38; 2.29)] was independent but not superior to that of serum LDH [HR 1.60 (95% CI 1.36; 2.29)]. A relatively small number of articles were eligible and there was considerable heterogeneity across the included studies. Serum biomarkers may provide relevant information on melanoma patient status and should be further researched. Serum S100B is a valid marker for diagnosis of melanoma recurrence. The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO; CRD42019137138).
Sections du résumé
BACKGROUND
BACKGROUND
Currently, no consensus on the use of blood tests for monitoring disease recurrence in patients with resected melanoma exists. The only meta-analysis conducted in 2008 found that elevated serum S100B levels were associated with significantly worse survival in melanoma patients. Serum LDH is an established prognostic factor in patients with advanced melanoma.
OBJECTIVE
OBJECTIVE
To compare the discriminative and prognostic ability of serum S100B with that of serum LDH in patients with melanoma.
METHODS
METHODS
This systematic review and meta-analysis were reported in accordance with the PRISMA Statement. The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO; CRD42019137138).
RESULTS
RESULTS
A quantitative analysis of data from 6 eligible studies included 1,033 patients with cutaneous melanoma. The discriminative ability of serum S100B at identifying disease relapse [pooled Area Under the ROC (AUROC) 78.64 (95% CI 70.28; 87.01)] was significantly greater than the discriminative ability of serum LDH [AUROC 64.41 (95% CI 56.05; 7278)] (p=0.013). Ten eligible studies with 1,987 patients were included in the risk of death analysis. The prognostic performance of serum S100B [pooled estimate of adjusted hazard ratio (HR) 1.78 (95% CI 1.38; 2.29)] was independent but not superior to that of serum LDH [HR 1.60 (95% CI 1.36; 2.29)].
LIMITATIONS
CONCLUSIONS
A relatively small number of articles were eligible and there was considerable heterogeneity across the included studies.
CONCLUSIONS
CONCLUSIONS
Serum biomarkers may provide relevant information on melanoma patient status and should be further researched. Serum S100B is a valid marker for diagnosis of melanoma recurrence.
SYSTEMATIC REVIEW REGISTRATION
BACKGROUND
The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO; CRD42019137138).
Identifiants
pubmed: 34950582
doi: 10.3389/fonc.2021.772165
pmc: PMC8688362
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
772165Informations de copyright
Copyright © 2021 Janka, Várvölgyi, Sipos, Soós, Hegyi, Kiss, Dembrovszky, Csupor, Kéringer, Pécsi, Solymár and Emri.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biochim Biophys Acta Mol Cell Res. 2019 Jul;1866(7):1197-1206
pubmed: 30392897
Melanoma Res. 2019 Feb;29(1):1-12
pubmed: 30308577
Ann Intern Med. 2019 Jan 1;170(1):W1-W33
pubmed: 30596876
Br J Cancer. 2012 Jul 24;107(3):422-8
pubmed: 22782342
Exp Dermatol. 2015 Apr;24(4):258-9
pubmed: 25496715
World J Biol Chem. 2013 Feb 26;4(1):1-12
pubmed: 23580916
BMJ. 2020 Aug 14;370:m2632
pubmed: 32816740
Melanoma Res. 2005 Oct;15(5):409-16
pubmed: 16179868
Melanoma Res. 2013 Oct;23(5):396-401
pubmed: 23907232
Oncoimmunology. 2016 Nov 1;5(12):e1249559
pubmed: 28123888
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Sci Rep. 2020 Oct 29;10(1):18665
pubmed: 33122776
J Invest Dermatol. 2016 Dec;136(12):2444-2452
pubmed: 27705749
J Dtsch Dermatol Ges. 2016 Feb;14(2):158-64
pubmed: 26819111
J Cell Mol Med. 2021 Feb;25(4):1972-1981
pubmed: 33377602
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
J Eur Acad Dermatol Venereol. 2012 Sep;26(9):1084-91
pubmed: 21838826
Mol Cancer. 2012 Oct 09;11:76
pubmed: 23043612
Br J Cancer. 2018 Aug;119(3):339-346
pubmed: 29950611
Clin Biochem. 2004 Jul;37(7):512-8
pubmed: 15234232
Cancers (Basel). 2020 Apr 28;12(5):
pubmed: 32354124
Hepatology. 1987 Nov-Dec;7(6):1346-58
pubmed: 3679094
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32221017
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Clin Cancer Res. 2011 Apr 15;17(8):2417-25
pubmed: 21487066
Mayo Clin Proc. 2014 Apr;89(4):429-33
pubmed: 24684870
EBioMedicine. 2015 May 12;2(7):671-80
pubmed: 26288839
Target Oncol. 2021 Mar;16(2):197-205
pubmed: 33555543
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):238-250
pubmed: 30291373
Lancet. 2018 Sep 15;392(10151):971-984
pubmed: 30238891
Anticancer Res. 2010 May;30(5):1799-805
pubmed: 20592382
Front Biosci (Schol Ed). 2011 Jun 01;3:1232-62
pubmed: 21622268
Int J Cancer. 2013 Jul;133(1):142-8
pubmed: 23238767
Cancer Immunol Res. 2017 Jun;5(6):480-492
pubmed: 28522460
BMJ. 2019 Jan 30;364:k4597
pubmed: 30700442
Cancer. 2011 Apr 15;117(8):1697-703
pubmed: 21472716
Oncoimmunology. 2018 Mar 6;7(7):e1438111
pubmed: 29900038
Mayo Clin Proc Innov Qual Outcomes. 2021 Oct 13;5(6):1012-1020
pubmed: 34703985
Int J Mol Sci. 2020 Jan 09;21(2):
pubmed: 31936623
J Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402
pubmed: 30959471
Methods Mol Biol. 2019;1929:691-700
pubmed: 30710305
Ann Thorac Surg. 2005 Jan;79(1):16-20
pubmed: 15620907
Amino Acids. 2012 Dec;43(6):2203-30
pubmed: 23053020
J Photochem Photobiol B. 2018 Aug;185:169-175
pubmed: 29936410
Ann Surg Oncol. 2013 Aug;20(8):2772-9
pubmed: 23512078
Mol Cancer. 2018 Aug 23;17(1):129
pubmed: 30139382
Ann Oncol. 2015 Sep;26 Suppl 5:v126-32
pubmed: 26314774
Tumour Biol. 2007;28(2):63-9
pubmed: 17264538
Cancers (Basel). 2020 Nov 03;12(11):
pubmed: 33153193
Med Oncol. 2001;18(2):109-20
pubmed: 11778756
Int Immunopharmacol. 2016 Nov;40:466-473
pubmed: 27728898
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Cancer. 2003 Apr 1;97(7):1737-45
pubmed: 12655531
Acta Oncol. 2015 Jul;54(7):961-70
pubmed: 25984930
PLoS One. 2013 Nov 28;8(11):e81624
pubmed: 24312329
Gen Physiol Biophys. 2009;28 Spec No Focus:F65-75
pubmed: 20093728
Front Oncol. 2018 Jul 18;8:270
pubmed: 30073150
Ann Intern Med. 2013 Feb 19;158(4):280-6
pubmed: 23420236
Tumour Biol. 2011 Dec;32(6):1155-61
pubmed: 21858537
Dermatology. 2006;213(3):187-91
pubmed: 17033166
Br J Dermatol. 1997 Sep;137(3):381-5
pubmed: 9349333
Endocrinology. 2018 May 1;159(5):1992-2007
pubmed: 29546369
Clin Chim Acta. 2014 Feb 15;429:168-74
pubmed: 24333389
Eur J Cancer. 2007 Mar;43(4):816-21
pubmed: 17276671
Front Pharmacol. 2018 Aug 14;9:856
pubmed: 30154717
Diagnostics (Basel). 2021 Jul 26;11(8):
pubmed: 34441278
Dermatol Res Pract. 2012;2012:260643
pubmed: 22287956
Eur J Surg Oncol. 2012 Apr;38(4):281-5
pubmed: 22240030
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1482-1488
pubmed: 31967695
Int J Mol Sci. 2020 Nov 26;21(23):
pubmed: 33256110
Int J Cancer. 2008 Nov 15;123(10):2370-6
pubmed: 18752249